QRG Capital Management Inc. Has $1.47 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

QRG Capital Management Inc. reduced its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 44.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 72,542 shares of the company’s stock after selling 58,327 shares during the quarter. QRG Capital Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,465,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TEVA. Cromwell Holdings LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares in the last quarter. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $41,000. Sound Income Strategies LLC raised its stake in Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after purchasing an additional 2,824 shares in the last quarter. JTC Employer Solutions Trustee Ltd bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $65,000. Finally, MAI Capital Management grew its position in shares of Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. This trade represents a 68.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 622,060 shares of company stock worth $17,076,965 over the last three months. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $31.38 on Wednesday. The business has a fifty day simple moving average of $29.27 and a 200 day simple moving average of $22.35. The company has a market cap of $35.99 billion, a P/E ratio of 52.30, a P/E/G ratio of 1.82 and a beta of 0.66. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $33.42.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TEVA. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Barclays began coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $33.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.